Precision medicine: Beyond newborn screening

Revity, Inc. was established in May 2023 as a science-based company that leverages innovation in life sciences and diagnostics to improve lives globally. Revvity Omics has replaced PerkinElmer Genomics as the company’s genomics services business. The organization builds on its legacy of screening 40 million babies annually across 110 countries for life-threatening diseases and leverages this expertise in the newborn screening ecosystem to provide pharmaceutical companies access to the latest advances in the field of genetics.  Revvity Omics combines this expertise with the force of its parent company, Revvity, Inc., and its proficiency in

Revvity Omics: expertise in drug development, from inception to market.  

No one wants to miss an opportunity for success, particularly in drug development. When pharmaceutical companies reach out to Revvity Omics only at a later stage in their drug development, they miss out on the deep expertise Revvity Omics brings to the early stages of drug creation and delivery. Companies who work with Revvity Omics early in the drug development process reap the benefits of close evaluation of the product and its intended use. This proactive approach also involves the development of a strategic plan for partnership and collaboration throughout the entire drug development

How the Clinical Reporting Team is the New Sherlock Holmes in Genetics

Patients with rare diseases have much to gain from whole genome testing. Many times a condition may be so rare that physicians have not diagnosed or seen that particular condition.   “On average from the time that a first symptom appears, an individual might see anywhere from 16 to 17 healthcare specialists before they get their diagnosis,” says Collins. “And that period of time on average is about seven to 10 years, which is a pretty significant amount of time that patients are searching for answers and trying to find out the cause of their medical issues.”

Interview with Dr. Hegde on the advances in genomic testing and the current landscape

Read this candid interview with Dr. Madhuri Hegde as she discusses the strategy of PerkinElmer Genomics of combining genomic sequencing with a functional enzyme assay, and why whole genome sequencing is our focus and mission. She also reflects on how genomic testing has advanced in the last five years and what that means for providers and their patients.